Schedule 13G ownership disclosure
Agios Pharmaceuticals Inc
Common Stock, $0.001 par value per share · CUSIP: 00847X104
Event date: 2025-08-21
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Paradigm BioCapital Advisors LP
Shares: 3,027,977.00 · Class: 5.2%
- Paradigm BioCapital Advisors GP LLC
Shares: 3,027,977.00 · Class: 5.2%
- Senai Asefaw, M.D.
Shares: 3,027,977.00 · Class: 5.2%
- Paradigm BioCapital International Fund Ltd.
Shares: 2,669,945.00 · Class: 4.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-084792
- Form type
- SCHEDULE 13G
- Filer
- AGIOS PHARMACEUTICALS, INC.
- CIK
- CIK 1439222
- Filed
- Aug 28, 2025
- Reporting period
- Aug 21, 2025
- Description
- Schedule 13G beneficial ownership